VDR gene polymorphisms: when to stratify clinical trial cohorts

The pill works, or it doesn't. This is the baseline assumption baked into most clinical protocols, most product marketing, and most patient conversations — and it is, biochemically speaking, embarrassingly incomplete.

Two people can ingest identical doses of vitamin D, sit at identical baseline serum 25-hydroxyvitamin D concentrations, and produce radically different biochemical responses because of variations in a single receptor gene that the industry has no commercial reason to discuss. The variable is the vitamin D receptor (VDR) — specifically, the constellation of single nucleotide polymorphisms along the VDR locus that alter receptor structure, mRNA stability, and downstream transcriptional efficiency. When clinical trials ignore these variants and treat the cohort as genetically homogeneous, they collapse the response of carriers of permissive alleles with carriers of restrictive alleles into a single mean value that describes no one in particular. Stratifying trial cohorts by VDR genotype is not methodological polish. It is the difference between resolving a real metabolic signal and watching it dissolve into statistical noise.

The dose on the label tells you nothing about the dose at the receptor.

The Mechanistic Foundation: How VDR Polymorphisms Rewire Transcription

The VDR is a nuclear transcription factor. After 1,25-dihydroxyvitamin D [1,25(OH)₂D] binds the ligand-binding domain, the receptor dimerizes with retinoid X receptor (RXR), translocates to the nucleus, and binds vitamin D response elements (VDREs) upstream of target genes. Every step in that cascade — ligand affinity, heterodimer stability, DNA contact, co-activator recruitment — is a candidate site for modulation by structural variants in the receptor itself.

Four SNPs dominate the VDR literature: FokI (rs10735810 / rs2228570), TaqI (rs731236), BsmI (rs1544410), and ApaI (rs7975232). They are not interchangeable, and pooling them into a single genetic "category" is the first analytical mistake. They sit in different regions of the gene, hit different parts of the transcription–translation pipeline, and produce categorically different mechanistic effects.

FokI is positioned on exon 2 and operates by altering the translation initiation site. The polymorphic variant produces a VDR protein shortened by three amino acids. A three-residue deletion sounds trivial until you remember that transcription factors are exquisitely sensitive to N-terminal structure; the shorter FokI isoform exhibits measurably altered functional activity compared with the longer reference isoform. ApaI, BsmI, and TaqI cluster near the 3' end of the VDR gene and act primarily through mRNA stability and post-transcriptional regulation rather than by altering the length of the encoded protein. The mechanistic distinction matters: a protein-coding variant should, in principle, produce effects that operate per receptor molecule, whereas 3' UTR variants modulate the quantity of receptor available without changing its sequence.

This dichotomy — coding-region functional variant versus regulatory-region expression variant — is the structural backbone of every VDR-stratification argument that follows. A trial that pools FokI and TaqI genotypes into a single "high-risk VDR" category has already discarded the only mechanistic distinction that justifies the stratification in the first place.

FokI Versus 3'-End Variants: What the Mechanistic Split Predicts

A useful way to think about the VDR polymorphism panel is as two functional classes rather than four individual SNPs. The table below summarizes the core mechanistic contrast that should drive any analytical decision.

The implication is straightforward. If your trial endpoint depends on the qualitative behavior of the receptor — its affinity for VDREs, its interaction with co-activators, its downstream transcriptional output per molecule — FokI is the relevant polymorphism. If your endpoint depends on how much receptor is available to do the work, the 3'-end cluster becomes relevant. Most vitamin D supplementation trials measure serum 25(OH)D, which sits upstream of both mechanisms, and so can be modulated by either class of variant depending on which limb of the pathway is rate-limiting in a given individual.

This is also why the meta-analytic literature refuses to deliver a clean answer when the four SNPs are lumped together. Pool FokI, TaqI, BsmI, and ApaI into a single genetic variable and you have averaged two distinct biological mechanisms into one statistical artifact. Stratify them and the signal emerges.

What the Meta-Analyses Actually Show

The strongest evidence that VDR stratification is non-optional comes from the Usategui-Martín et al. (2022) systematic review and meta-analysis, which pooled 8 studies and 1,038 subjects specifically to test whether baseline VDR genotype predicts the magnitude of the serum 25(OH)D response to vitamin D supplementation. The results are not subtle.

Carriers of the FF genotype of the FokI variant showed a significantly larger 25(OH)D response to supplementation than carriers of the alternative allele (p < 0.001). Carriers of the variant allele of TaqI — the Tt + tt combined group — also showed a significantly greater response (p = 0.02). These are not borderline signals awaiting replication; they are the kind of effect sizes that survive meta-analytic pooling across heterogeneous populations and supplementation regimens.

For the other two classical SNPs, the same meta-analysis found no overall statistically significant association with 25(OH)D response: ApaI returned p = 0.63 and BsmI returned p = 0.081. Read those numbers correctly. They do not say that ApaI and BsmI are biologically inert. They say that, when the entire pooled cohort is analyzed without subgroup stratification, the association with 25(OH)D response is not detectable. That distinction matters because the second major meta-analysis of the field — a 2022 review of 16 randomized controlled trials comprising 2,994 cases — explicitly demonstrated that VDR-by-supplementation interactions on serum 25(OH)D and metabolic traits become statistically significant once the analysis is stratified by study duration, gender, age, BMI, baseline health status, and race. The signal is there. It is hidden by the same covariates that every clinical trial already collects and most trials still ignore during their genotype analyses.

The picture is therefore this: two of the four classical VDR SNPs (FokI, TaqI) predict supplementation response at the pooled meta-analytic level. The other two (ApaI, BsmI) require subgroup stratification before their effects emerge. And the magnitude of every one of these signals is modulated by demographic and clinical covariates that the supplement industry has zero interest in measuring.

A "non-responder" is, more often than not, an ungenotyped responder.

Integrating VDR Stratification Into Randomized Controlled Trial Design

Pretending a trial cohort is genetically homogeneous when it is not is not a benign methodological shortcut. It is a source of systematic bias that inflates variance, attenuates effect sizes, and produces the kind of disappointing null results that get re-branded as "vitamin D doesn't work for outcome X" in press releases. The fix is procedural, not conceptual. Here is the minimum stratification protocol any serious VDR-aware trial should adopt.

1. Genotype all enrolled participants for FokI, TaqI, BsmI, and ApaI at baseline. Anything less is under-powered for the FokI signal that the meta-analytic data already predicts.

2. Pre-specify genotype subgroups in the statistical analysis plan before unblinding. Post-hoc stratification after seeing the data is a fishing license, not a method.

3. Stratify randomization by FokI genotype at minimum. Block randomization within FokI strata prevents the chance imbalance in a small trial from masking the very signal the study is designed to detect.

4. Report 25(OH)D response by genotype subgroup as a primary or co-primary endpoint. A pooled mean that hides a meaningful difference between FokI subgroups is not a neutral summary; it is a misleading one.

5. Pre-register the interaction analysis between VDR genotype and supplementation dose. The pharmacogenomic question is not "does supplementation work" but "does supplementation work in carriers of this allele at this dose" — and that question requires a pre-specified interaction term.

6. Stratify or adjust for BMI, age, sex, baseline 25(OH)D, and race in the genotype-response model. The 2,994-case meta-analysis showed these covariates are not nuisance variables; they are effect modifiers.

7. Power the trial on the smallest genotype subgroup of interest, not on the pooled cohort. This almost always means recruiting more participants than the unstratified power calculation suggested, and it almost always produces a cleaner result.

The supplement industry will not adopt any of these steps voluntarily, because the entire business model depends on the premise that one dose fits all genotypes. The clinical trial community should adopt them because the meta-analytic evidence base has been saying the same thing for several years and the field keeps acting surprised each time a new "vitamin D didn't work" trial fails to replicate.

The Confounder Problem: Why a Single SNP Cannot Tell the Whole Story

Genotype does not operate in a vacuum. The 2,994-case meta-analysis showed clearly that VDR-by-supplementation interactions on 25(OH)D and metabolic traits become statistically significant only when the analysis is stratified by study duration, gender, age, BMI, health status, and race. Treat those covariates as nuisance variables and the genetic signal vanishes. Treat them as effect modifiers and the genetic signal resolves into something clinically actionable.

This creates a methodological bind for any trial that wants to use VDR stratification prospectively. A 25-year-old normal-weight woman of European ancestry and a 65-year-old obese man of South Asian ancestry carrying the same FokI allele will not respond identically to identical supplementation, and the difference is not noise. BMI modifies vitamin D sequestration in adipose tissue, age modifies renal 1α-hydroxylase activity, race modifies baseline cutaneous synthesis and unmeasured genetic background, and sex modifies the hormonal environment in which VDR signaling operates. Pre-specified subgroup analyses are the only honest way to handle this; pooled estimates are the only way to bury it.

There is also the open question of epistasis. The four classical SNPs do not exhaust VDR variation. Less-studied variants may exert synergistic or antagonistic effects in combination with FokI and TaqI, and food fortification trials in particular — where the dose is mandatory and the exposure is population-wide — generate exactly the kind of heterogeneous genetic background where epistatic effects become statistically detectable. The current evidence base cannot answer that question, and the unknowns should be acknowledged rather than papered over with a confident summary statement. A "non-responder" without baseline genotype data is not a clinical fact; it is the placebo arm's mirror image.

The honest position is this: VDR genotyping is not a universal regulatory mandate for every food fortification trial, and no responsible reviewer should claim otherwise. It is, however, a methodological requirement for any trial whose primary endpoint depends on the magnitude of an individual's serum 25(OH)D response or on the downstream metabolic consequences of that response. Pretending otherwise has cost the field years of underpowered, mis-stratified, and ultimately uninformative trials — the kind that get cited as "negative evidence" by people who never read the methods section closely enough to notice that the placebo and the active arm were genetically non-comparable from the outset.

The Verdict From the Bench

The mechanistic case is closed. The meta-analytic case is closed. The methodological case has been obvious since the first VDR-stratified supplementation trial returned a stronger signal in carriers of a permissive allele than in pooled analyses. Cohort stratification by VDR genotype — FokI at minimum, the 3'-end cluster as a secondary panel, with BMI, age, sex, and race as pre-specified effect modifiers — is the minimum standard for any clinical trial that intends to measure a real vitamin D response rather than a population average of incompatible individual responses.

The "one dose fits all genotypes" model is not science. It is a myth dressed in a lab coat. And the bench has the serum data to prove it.